Adopting PROs in virtual and outpatient management of RA by Taylor, PC

The opportunities and challenges of telemedicine in the management of people with rheumatoid arthritis by Taylor, PC

JAK inhibitors in rheumatoid arthritis by Taylor, PC

Aetiopathology of rheumatoid arthritis by Taylor, PC, Kiriakidis, S

Aetiopathology of rheumatoid arthritis by Taylor, PC, Narayan, N

Pain in rheumatoid arthritis - Could JAK inhibition be the answer? by Mehta, P, Taylor, PC

Treating-to-target or treating the patient in rheumatoid arthritis? by Taylor, PC, Pope, J

Central sensitisation: causes, therapies, and terminology by Mehta, P, Ciurtin, C, Rahman, A, Taylor, PC

Macrophage targeted positron emission tomography–computed tomography in rheumatoid arthritis: results of a pilot study by Narayan, N, Carlucci, F, Saleem, A, Taylor, PC

The Clinical Features, Pathogenesis and Methotrexate Therapy of Chronic Chikungunya Arthritis by Amaral, JK, Taylor, PC, Teixeira, MM, Morrison, TE, Schoen, RT

Outcomes following Adalimumab bio-originator to biosimilar switch - a comparison using real-world patient and physician reported data in European countries by Taylor, PC, Sanchez Gonzalez, Y, Clark, R, Faccin, F, Howell, O

Approaches to optimising access to NICE-approved biologic anti-TNFs for patients with rheumatoid arthritis with moderately active disease by Taylor, PC, Askari, A, Choy, E, Ehrenstein, MR, Else, S, Nisar, MK

Quality of care in rheumatoid disease from the clinician perspective: a modified Delphi Panel approach by O’Shea, F, Taylor, PC, Dickie, G, Yaworsky, A, Banderas, B, Kachroo, S

The JAK inhibitor baricitinib inhibits oncostatin M induction of proinflammatory mediators in ex-vivo synovial derived cells by Weston, S, Macdonald, JL, Williams, LM, Roussou, E, Kang, NV, Kiriakidis, S, Taylor, PC

Targeted literature review of current treatments and unmet need in moderate rheumatoid arthritis in the United Kingdom by Taylor, PC, Woods, M, Rycroft, C, Patel, P, Blanthorn-Hazell, S, Kent, T, Bukhari, M

The key comorbidities in patients with rheumatoid arthritis: a narrative review by Taylor, PC, Atzeni, F, Balsa, A, Gossec, L, Müller-Ladner, U, Pope, J

Neutralizing monoclonal antibodies for treatment of COVID-19 by Taylor, PC, Adams, AC, Hufford, MM, De La Torre, I, Winthrop, K, Gottlieb, RL

Itch as major mediator of effect of tofacitinib on health-related quality of life in psoriatic arthritis: a mediation analysis by Taylor, PC, Bushmakin, AG, Cappelleri, JC, Young, P, Germino, R, Merola, JF, Yosipovitch, G

Rapid and concurrent improvements in patient-reported outcomes of rheumatoid arthritis with baricitinib in RA-BEAM by Strand, V, Sebba, A, Jia, B, Birt, J, Quebe, A, Zhang, H, Taylor, PC

The Jak/STAT pathway: a focus on pain in rheumatoid arthritis by Simon, LS, Taylor, PC, Choy, EH, Sebba, A, Quebe, A, Knopp, KL, Porreca, F